Emerging Role of Cytoreductive Prostatectomy in Patients with Metastatic Disease

Overview

Journal Transl Androl Urol

Date 2018 Oct 27

PMID 30363448

Citations 3

Authors

Yasmeen Jaber

Chad A Reichard

Brian F Chapin

Affiliations

Soon will be listed here.

Abstract

Traditionally, systemic androgen deprivation therapy (ADT) has been the primary treatment modality in metastatic prostate cancer (mPCa) while treatment of the primary tumor has been reserved for patients with clinically localized disease. Emerging data suggests that treating the primary tumor in patients with metastatic disease may provide a survival benefit. However, these studies are fraught with selection bias towards patients with favorable disease characteristics. Despite these limitations, clinicians are becoming increasingly interested in consolidative treatment of the primary tumor in this setting. Many translational models and observational studies of cytoreduction in mPCa have yielded compelling results, suggesting a potential biological and clinical benefit. While there are no published randomized control trials on cytoreduction in mPCa, the literature regarding safety, feasibility, and potential symptomatic benefit of cytoreductive prostatectomy (CRP) in mPCa supports further investigation. Thus, MEDLINE and PubMed electronic databases were queried for English language articles related to patients with mPCa who underwent radical prostatectomy. Keywords used include: cytoreductive prostatectomy, radical prostatectomy, oligometastatic, mPCa, and oligometastasis. In this review we examine the literature regarding the feasibility of CRP as well as the reported oncologic outcomes, limitations of the literature, and future directions. Since there is currently no level one evidence to support its use, CRP should not be applied outside a clinical trial. A better understanding of the biology driving mPCa, in conjunction with standardization of clinical trials, will help expedite actionable data acquisition that may improve clinical outcomes.

Citing Articles

Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer.

McCormick B, Chery L, Chapin B Transl Androl Urol. 2021; 10(5):2178-2187.

PMID: 34159100 PMC: 8185652. DOI: 10.21037/tau-20-1002.

Cancer biology as revealed by the research autopsy.

Iacobuzio-Donahue C, Michael C, Baez P, Kappagantula R, Hooper J, Hollman T Nat Rev Cancer. 2019; 19(12):686-697.

PMID: 31519982 PMC: 7453489. DOI: 10.1038/s41568-019-0199-4.

Potential biological and clinical benefit of prostate-directed interventions in patients with metastatic prostate cancer.

Miyake M, Owari T, Tanaka N, Fujimoto K Ann Transl Med. 2019; 7(Suppl 1):S46.

PMID: 31032325 PMC: 6462632. DOI: 10.21037/atm.2019.02.30.

References

Bayne C, Williams S, Cooperberg M, Gleave M, Graefen M, Montorsi F . Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol. 2015; 69(5):775-87. DOI: 10.1016/j.eururo.2015.04.036. View

Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway C . Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011; 29(18):2574-81. PMC: 3138635. DOI: 10.1200/JCO.2010.33.2999. View

Ahmed K, Barney B, Davis B, Park S, Kwon E, Olivier K . Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2013; 2:215. PMC: 3551203. DOI: 10.3389/fonc.2012.00215. View

Tosoian J, Gorin M, Ross A, Pienta K, Tran P, Schaeffer E . Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2016; 14(1):15-25. PMC: 5808411. DOI: 10.1038/nrurol.2016.175. View

Roach P, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G . The Impact of Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med. 2017; 59(1):82-88. DOI: 10.2967/jnumed.117.197160. View

Cifuentes F, Valenzuela R, Contreras H, Castellon E . Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer. Oncol Rep. 2015; 34(6):2837-44. PMC: 4722890. DOI: 10.3892/or.2015.4319. View

Won A, Gurney H, Marx G, de Souza P, Patel M . Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013; 112(4):E250-5. DOI: 10.1111/bju.12169. View

Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P . A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. Eur Urol. 2015; 69(5):788-94. DOI: 10.1016/j.eururo.2015.05.023. View

Rycaj K, Tang D . Molecular determinants of prostate cancer metastasis. Oncotarget. 2017; 8(50):88211-88231. PMC: 5675705. DOI: 10.18632/oncotarget.21085. View

10.

Sceneay J, Smyth M, Moller A . The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013; 32(3-4):449-64. DOI: 10.1007/s10555-013-9420-1. View

11.

Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B . Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol. 2010; 58(1):1-7. DOI: 10.1016/j.eururo.2010.03.001. View

12.

Schumacher M, Burkhard F, Thalmann G, Fleischmann A, Studer U . Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol. 2008; 54(2):344-52. DOI: 10.1016/j.eururo.2008.05.023. View

13.

James N, de Bono J, Spears M, Clarke N, Mason M, Dearnaley D . Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017; 377(4):338-351. PMC: 5533216. DOI: 10.1056/NEJMoa1702900. View

14.

Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N . Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2012; 11(1):27-32. DOI: 10.1016/j.clgc.2012.08.003. View

15.

Van den Bergh L, Lerut E, Haustermans K, Deroose C, Oyen R, Isebaert S . Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol. 2015; 33(3):109.e23-31. DOI: 10.1016/j.urolonc.2014.11.008. View

16.

Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T . Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013; 52(8):1622-8. DOI: 10.3109/0284186X.2013.764010. View

17.

Sanchez C, Andahur E, Valenzuela R, Castellon E, Fulla J, Ramos C . Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 2015; 7(4):3993-4008. PMC: 4826185. DOI: 10.18632/oncotarget.6540. View

18.

Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J . Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow. Cancer Res. 2016; 76(8):2453-64. DOI: 10.1158/0008-5472.CAN-15-2340. View

19.

Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisenberger M . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373(8):737-46. PMC: 4562797. DOI: 10.1056/NEJMoa1503747. View

20.

Moschini M, Soria F, Briganti A, Shariat S . The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. Prostate Cancer Prostatic Dis. 2016; 20(1):7-11. DOI: 10.1038/pcan.2016.52. View